Patents Assigned to Hoffman-La Roche Inc.
  • Patent number: 10005736
    Abstract: The present invention relates to compounds of formula I wherein R1? is CH3 R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl or cyclopropyl; R3 is Cl, F, CF3, cyano, methyl, methoxy or cyclopropyl; R4 is hydrogen, methyl or F; X is N or CH; Y is N or CH; with the proviso that X and Y are not simultaneously CH; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: June 26, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Marius Hoener, Juergen Wichmann
  • Patent number: 9980929
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: May 29, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Benoit Hornsperger, Roberto Iacone, Bernd Kuhn, Hans P. Maerki, Peter Mohr, Michael Reutlinger
  • Patent number: 9957261
    Abstract: The present invention relates to compounds TAAR receptor antagonists of formula I wherein X, R, L, Ar and R1 are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric disorders with compounds of formula I.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: May 1, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Giuseppe Cecere, Guido Galley, Annick Goergler, Roger Norcross, Philippe Pflieger, Alina Tirla, Philipp Schmid
  • Patent number: 9949966
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: April 24, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Xingchun Han, Hassan Javanbakht, Min Jiang, Chungen Liang, Jianping Wang, Yongguang Wang, Zhanguo Wang, Robert James Weikert, Song Yang, Chengang Zhou
  • Patent number: 9944719
    Abstract: The present invention relates to antibody-based dual targeting molecules, and to methods for generating such dual targeting molecules, including a library-based approach.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: April 17, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Roland Beckmann, Kristian Jensen
  • Patent number: 9920049
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X and Y are as described in the description and in the claims, as well as or pharmaceutically acceptable salts, or enantiomers, or diastereomers thereof. The invention also contains compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: March 20, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Song Yang, Xingchun Han, Zhanguo Wang
  • Patent number: 9902701
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, X and a are as described in the description and in the claims, as well as or pharmaceutically acceptable salts thereof. The invention also contains compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: February 27, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Song Yang, Chungen Liang, Jianping Wang, Song Pan
  • Patent number: 9879095
    Abstract: The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: January 30, 2018
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Ulrich Brinkmann, Alexander Haas, Silke Metz, Juergen Michael Schanzer
  • Patent number: 9845347
    Abstract: A method for cultivating a bacterial cell comprising the addition of an amino acid in an alkaline solution used for pH regulation. Also an aspect is a method for producing a polypeptide comprising the steps of a) providing a bacterial cell comprising a nucleic acid encoding the polypeptide, b) cultivating the provided cell, c) adjusting the pH value during the cultivating with a basic solution comprising an amino acid, d) recovering the polypeptide from the cell or the cultivation medium and thereby producing the polypeptide.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: December 19, 2017
    Assignee: Hoffman-La Roche Inc.
    Inventor: Christian Schantz
  • Patent number: 9802920
    Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: October 31, 2017
    Assignees: Hoffman-La Roche Inc., Chugai Pharamceutical Co.
    Inventors: Romyr Dominique, Norman Kong, Yan Lou, Francisco Javier Lopez-Tapia, Sung-Sau So
  • Patent number: 9783611
    Abstract: The invention relates to specific anti-HER3 antibodies, that bind to the beta-hairpin of HER3, their preparation and use as medicament.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: October 10, 2017
    Assignee: Hoffman-La Roche Inc.
    Inventors: Birgit Bossenmaier, Richard Buick, Michael Gerg, Frank Kroner, Gerhard Niederfellner, Carmen Peess, Michael Schraeml
  • Patent number: 9751870
    Abstract: The invention relates to the use of a compound of formula I wherein A1 is phenyl or a five or six membered hereroaryl group, containing 1, 2 or 3 heteroatoms, selected from N or S; R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen or cycloalkyl; A2 is phenyl; R2 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cyano, S-lower alkyl substituted by halogen, S(O)2-lower alkyl substituted by halogen; n is 1 or 2; or a pharmaceutically acceptable acid addition salt, or a racemic mixture or its corresponding enantiomer and/or optical isomers thereof, for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrome.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: September 5, 2017
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Caterina Bissantz, Christophe Grundschober, Matthias Nettekoven, Jean-Marc Plancher, Walter Vifian
  • Patent number: 9701691
    Abstract: The present invention relates to the use of novel compounds of Formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: July 11, 2017
    Assignee: Hoffman-La Roche Inc.
    Inventors: Shaoqing Chen, Johannes Cornelius Hermann, Nam T. Le, Matthew C. Lucas, Fernando Padilla
  • Patent number: 9663517
    Abstract: Provided are solid dispersions, solid molecular complexes, salts and crystalline polymorphs involving propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: May 30, 2017
    Assignees: Plexxikon Inc., Hoffman-La Roche Inc.
    Inventors: Dipen Desai, Ralph Diodone, Zenaida Go, Prabha N. Ibrahim, Raman Iyer, Hans-Juergen Mair, Harpreet K. Sandhu, Navnit H. Shah, Gary Visor, Nicole Wyttenbach, Stephan Lauper, Johannes Pudewell, Frank Wierschem
  • Patent number: 9657351
    Abstract: Use of at least an MDM2 gene panel, preferably a four gene MDM2 gene panel, as a biomarker for predicting the response to a MDM2 antagonist.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: May 23, 2017
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Hua Zhong, David Geho, Gong Chen, Gwen Nichols, Markus Dangl
  • Patent number: 9636339
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A1 and n are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: May 2, 2017
    Assignee: Hoffman-La Roche Inc.
    Inventors: Johannes Aebi, Kurt Amrein, Robert Britton, Benoit Hornsperger, Bernd Kuhn, Hans P. Maerki, Rainer E. Martin, Alexander V. Mayweg, Xuefei Tan
  • Patent number: 9617342
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: April 11, 2017
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • Patent number: 9604977
    Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A, E and n are as described herein, compositions including the compounds and methods of using the compounds as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors for the treatment or prophylaxis of type 2 diabetes, atherosclerosis, chronic kidney diseases, non-alcoholic steatohepatitis and cancer.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: March 28, 2017
    Assignee: Hoffman-La Roche Inc.
    Inventors: Bernd Buettelmann, Simona M. Ceccarelli, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
  • Patent number: 9556172
    Abstract: According to the present invention there are provided novel processes for the manufacture of the compound of formula 1 as well as intermediates and novel synthesis routes for key intermediates used in those processes.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: January 31, 2017
    Assignee: Hoffman La-Roche Inc.
    Inventors: Corey James Brumsted, Hendrik Moorlag, Roumen Nikolaev Radinov, Yi Ren, Pius Waldmeier
  • Patent number: 9446204
    Abstract: The invention relates to a safety device for an injection syringe, the injection syringe including a body having an injection needle fitted thereon, the device including a plunger rod including a distal plunger part slidably movable in the body of the syringe, and a proximal triggering part, configured to trigger the displacement of a protection sheath, from an injection position, wherein the needle is uncovered, towards a safety position, wherein the needle is covered by the sheath. The proximal triggering part is able to move relative to the distal plunger part once the distal plunger part is at the distal end of its stroke, to trigger the displacement of the protection sheath.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: September 20, 2016
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Mark Digby Teucher, Pascal Dugand, Loïc Sebileau, Daniel Peter, Maxime Gaillot, Jürg Liniger